Skip to main content

Table 1 Demographic information of the included patients

From: Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China

Clinical subjects

Number of patients

Proportion (%)

Age, (years)

 18–45

51

5.44

 46–65

572

60.98

  > 65

315

33.58

Gender

 Female

388

41.36

 Male

550

58.64

Marital status

 Married

933

99.47

 Unmarried

5

0.53

History of smoking

 None

436

46.48

 Yes

501

53.41

 Unknown

1

0.11

Alcohol consumption

 None

703

74.95

 Yes

234

24.94

 Unknown

1

0.11

Family history of tumor

 None

754

80.38

 Yes

183

19.51

 Unknown

1

0.11

KPS

 10–40

7

0.75

 50–70

128

13.65

 80–100

395

42.11

 Unknown

408

43.49

Lymph node metastasis

 None

368

39.23

 Yes

537

57.25

 Unknown

33

3.52

Pathology

 Small-cell

69

7.36

 Adenocarcinoma

331

35.29

 Squamous cell

124

13.22

 Large cell

13

1.38

 Mixed

22

2.34

 Others (unknown)

379

40.41

ALP

  < 102.00 mmol/L

347

36.99

  ≥ 102.00 mmol/L

355

37.85

 Unknown

236

25.16

LDH

  < 215.00 U/L

420

44.78

  ≥ 215.00 U/L

438

46.70

 Unknown

80

8.52

CEA

  < 15.64 ng/ml

404

43.07

  ≥ 15.64 ng/ml

405

43.18

 Unknown

129

13.75

SCC

  < 0.80 ng/ml

402

42.86

  ≥ 0.80 ng/ml

404

43.07

 Unknown

132

14.07

Cyfra21–1

  < 4.93 ng/ml

401

42.75

  ≥ 4.93 ng/ml

401

42.75

 Unknown

136

14.50

NSE

  < 16.67 ng/ml

401

42.75

  ≥ 16.67 ng/ml

402

42.86

 Unknown

135

14.39

  1. KPS Karnofsky score, ALP Alkaline phosphatase, LDH Lactate dehydrogenase, CEA Carcinoembryonic antigen, SCC Squamous cell carcinoma antigen, Cyfra21–1 Cytokeratin-19 fragment, NSE Neuron specific enolase